Cyclarity develops advanced sensor technology for real-time monitoring and analysis of subsurface infrastructure integrity. Their solutions provide actionable data to predict failures and optimize maintenance schedules for pipelines and utilities. This proactive approach reduces operational risk and extends the lifespan of essential buried assets.
Funding
$24.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Atherosclerosis, the buildup of arterial plaque, is a leading cause of cardiovascular diseases, including heart attack and stroke, responsible for a significant percentage of deaths worldwide. Current treatments slow disease progression or address CVD events but do not reverse the underlying plaque accumulation. Toxic oxidized cholesterol derivatives, such as 7-ketocholesterol (7KC), are key drivers of atherosclerosis and other age-related diseases.
Solution
Cyclarity Therapeutics develops disease-modifying therapeutics that target and remove toxic oxidized cholesterol to reverse atherosclerosis and prevent future cardiovascular events. The company's lead product, UDP-003, is a custom-engineered cyclodextrin designed to capture and eliminate oxidized cholesterol derivatives, restoring cardiovascular self-repair function and reducing arterial plaque. Cyclarity employs a proprietary discovery platform that combines computational and synthetic chemistry to create cyclodextrins tailored to specific oxidized cholesterol targets. This platform enables the company to model cyclodextrins, run virtual experiments, and perform molecular-dynamic analyses to optimize target specificity and minimize off-target effects.
Target Audience
The primary target audience includes individuals at risk of or affected by atherosclerosis, primary coronary artery disease, and associated cardiovascular diseases, as well as those seeking preventative therapies for age-related conditions.
Features
- UDP-003, a first-in-class drug, targets and removes toxic oxidized cholesterol, a key driver of atherosclerosis.
- Custom-engineered cyclodextrins with maximized affinity for oxidized cholesterol.
- Proprietary discovery platform for modeling and testing cyclodextrin candidates against targeted and non-targeted molecules.
- Ability to rehabilitate diseased foam cells into healthy, functional macrophages.
- Designed to restore the cardiovascular self-repair function and reduce arterial plaque.
- Potential for repurposing for Alzheimer’s disease, kidney disease, and liver disease.
- Hydrophilic shell and hydrophobic core enable encapsulation and removal of hydrophobic molecules.